Related Experiment Video
Updated: Aug 25, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
Published on: May 12, 2019
Scope and epidemiology of cancer therapy-induced oral and gastrointestinal mucositis
Elenir B C Avritscher1, Catherine D Cooksley, Linda S Elting
1Section of Health Services Research, Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030-4009, USA.
Objective:
To discuss the scope and epidemiology of cancer therapy-induced mucositis.
Data Source:
Peer-reviewed articles and book chapters.
Conclusion:
Mucositis is a frequent and costly complication of cancer treatment. The risk of cancer therapy-induced mucositis varies depending on a number of patient- and treatment-related factors.
Implications For Nursing Practice:
An awareness of the risk factors associated with mucositis will allow nurses to identify cancer patients at greatest risk and incorporate supportive care measures into their management plans.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease III: Clinical Manifestations and Complications
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Oral Microbiota
Tumor Immunotherapy